首页> 外文OA文献 >Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m 2 ) in combination with lenalidomide and dexamethasone

【2h】

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m 2 ) in combination with lenalidomide and dexamethasone

机译：对MRD响应的定制治疗方法：使用高剂量两次胭脂红唑（45和56mg / m 2）的新诊断的多发性骨髓瘤患者的一期I / II研究与Lenalidomide和地塞米松组合

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Neha Korde; Donna Mastey; Elizabet Tavitian; Sham Mailankody; Alexander Lesokhin; Hani Hassoun; Eric L. Smith; Nikoletta Lendvai; Malin Hultcrantz; Urvi Shah; Carlyn Tan; Sydney Lu; Benjamin Diamond; Meghan Salcedo; Kelly Werner; David J. Chung; Michael Scordo; Gunjan L. Shah; Oscar Lahoud; Heather Landau; Maria Arcila; Caleb Ho; Mikhail Roshal; Ahmet Dogan; Andriy Derkach; Sean M. Devlin; Sergio A. Giralt; Ola Landgren;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m(2)) in Combination with Lenalidomide and Dexamethasone [J] . Korde Neha, Mastey Donna, Mailankody Sham, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：MRD响应驱动的阶段I / II研究用于新诊断的多发性骨髓瘤患者，使用较高剂量的两次胭脂红唑（45和56mg / m（2））与Lenalidomide和地塞米松组合
2. Elderly multiple myeloma (MM) patients, who are generally ineligible for transplantation, have high risks of death and treatment discontinuation, and require a regimen incorporating novel agents that balance safety, tolerability, and efficacy. We evaluated alternating bortezomib-dexamethasone and lenalidomide-dexamethasone treatments administered over a 63-day cycle in transplant-ineligible elderly patients with newly diagnosed MM. Subcutaneous bortezomib 1.3 mg/m2 was administered weekly on Days 1, 8, 15, and 22; oral lenalidomide 15 mg daily on Days 36-56; and oral dexamethasone 20 mg on Days 1, 8, 15, 22, 36, 43, 50, and 57 for 6 cycles. The primary endpoint was the overall response rate. [J] . Yokoyama Akihiro, Kada Akiko, Saito Akiko M., Acta medica Okayama . 2019,第6期

机译：通常不适合移植的老年多发性骨髓瘤（MM）患者具有很高的死亡和中止治疗的风险，因此需要一种方案，该方案应采用能够平衡安全性，耐受性和疗效的新型药物。我们评估了在不适合移植的老年初诊MM患者中，硼替佐米-地塞米松和来那度胺-地塞米松在63天周期内的交替治疗。在第1、8、15和22天每周一次皮下注射硼替佐米1.3 mg / m2;在第36-56天每天口服来那度胺15 mg;在第1、8、15、22、36、43、50和57天，口服地塞米松20 mg，共6个周期。主要终点是总体缓解率。
3. Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyeLome (IFM) Krd Phase II Study [J] . Roussel Murielle, Lauwers-Cances Valerie, Robillard Nelly, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：卡非佐米，来那度胺和地塞米松（KRd）诱导的一线治疗，然后是新诊断的多发性骨髓瘤（NDMM）患者的自体干细胞移植，Krd合并和来那度胺维持：组间法语国语双歧双歧（IFM）Krd II期研究的主要结果
4. RISK-ADAPTED INTRAVENOUS MELPHALAN WITH ADJUVANT THALIDOMIDE AND DEXAMETHASONE FOR NEWLY DIAGNOSED UNTREATED PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS: INTERIM REPORT OF A PHASE II TRIAL [C] . RL Comenzo, P Zhou, L Reich, International Symposium on Amyloidosis . 2005

机译：风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松，用于新诊断的未经治疗的全身淀粉样蛋白症患者：II期试验的中期报告
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study [O] . Meletios Dimopoulos, Michael Wang, Vladimir Maisnar, 2018

机译：在III期ASPIRE研究中使用卡非佐米来那度胺和地塞米松（KRd）与来那度胺和地塞米松（Rd）治疗的复发性多发性骨髓瘤患者根据计划的治疗持续时间无应答和无进展生存
7. A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma [O] . Melissa Alsina, Ola Landgren, Noopur Raje, 2020

机译：患有新诊断的多发性骨髓瘤的患者曾经每周胭脂红唑和近红外甲型酮相结合的1B阶段研究

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m 2 ) in combination with lenalidomide and dexamethasone

著录项

相似文献

相关主题

期刊订阅